The search for novel therapies that complement vaccine-induced immune protection against SARS-CoV-2 continues. In previous work, researchers at QIMR Berghofer Medical Research Institute and collaborators developed a cell-permeable and highly selective peptide called NACE2i, targeting nuclear angiotensin-converting enzyme 2 (ACE2). In particular, NACE2i spans and targets the ACE2 nuclear localization signal motif, successfully inhibiting nuclear translocation of ACE2 and viral replication in human cell lines infected with SARS-CoV-2.
Researchers from Central Drug Research Institute (CDRI) and Academy of Scientific & Innovative Research (AcSIR) have discovered novel antiplasmodial agents.
Aicuris Anti-infective Cures AG has announced its intention to focus on the development and commercialization of anti-infectives for immunocompromised individuals, and will discontinue research activities outside of this strategic scope.
Edding Group Co. Ltd. announced June 23 it filed for an IPO on the Hong Kong Exchange – news that comes amid a steep drop in China’s biopharma IPO market forecasting sluggish activity in a near-frozen “capital winter.”
Moderna Inc. may have risen to prominence during the pandemic with its messenger RNA (mRNA)-based COVID-19 vaccine, but it’s now casting a net far larger and wider. The company said on July 5 that it is readying international approval for its second mRNA vaccine called mRNA-1345 for respiratory syncytial virus (RSV)-associated acute respiratory disease based on positive interim data from the ongoing Conquer RSV study in individuals 60 and older.
In a move to address both prevention and treatment of hepatitis B virus (HBV), Brii Biosciences Ltd. has acquired from VBI Vaccines Inc. a global exclusive license to HBV therapeutic vaccine BRII-179 (VBI-2601) and an exclusive license for HBV prophylactic vaccine Prehevbri in the Asia Pacific region, excluding Japan.
Researchers at Shanghai Institute of Materia Medica and the Wuhan Institute of Virology Chinese Academy of Sciences have prepared and tested cyclic bisbenzyl tetrahydroisoquinoline compounds reported to be useful for the treatment of fibrosis, viral infections and inflammatory disorders.
Rapid point-of-care diagnostics company Lumos Diagnostics Inc. saw its stock shoot up 327% on the news that it finally gained U.S. FDA 510(k) clearance for its Febridx rapid, point-of-care test for bacterial infections. Febridx is a finger prick blood test that can indicate if a person has a bacterial or viral acute respiratory infection within 10 minutes.
The U.S. Department of Defense (DOD) has awarded Evotec SE’s subsidiary Just-Evotec Biologics Inc. a contract valued up to US$74 million for the rapid development of monoclonal antibody (MAb)-based drug product prototypes targeting orthopoxviruses.
Parasitic diseases caused by trypanosomatid protozoa have long been treated with traditional methods. However, the effectiveness of current treatments for leishmaniasis is limited. Some are toxic, or have been abandoned, such as in the cases of Chagas disease and human African trypanosomiasis (HAT), commonly known as sleeping sickness.
RSS
